Ocular Hypertension clinical trials at UCSD
2 in progress, 1 open to eligible people
18 Month Prospective Efficacy and Safety Study of Bimatoprost Intracameral Implant (DURYSTA)
open to eligible people ages 18 years and up
Study to collect effectiveness and safety data after administration of a bimatoprost intracameral implant in patients with open-angle glaucoma (OAG) or ocular hypertension (OHT).
La Jolla, California and other locations
Long-term Safety and Efficacy Extension Trial of Bimatoprost SR
Sorry, accepting new patients by invitation only
This study will evaluate the long-term safety and efficacy of Bimatoprost Sustained Release (SR) in patients with open-angle glaucoma or ocular hypertension who completed 1 of the 4 Phase 3 Bimatoprost SR studies (192024-091, -092, -093, or -095) and received Bimatoprost SR or who received commercial DURYSTA (Bimatoprost SR) in the open-label Phase 4 ARGOS study (MED-MA-EYE-0648) and completed (or exited early from) the study.
La Jolla, California and other locations
Last updated: